Risk Communications Panel To Discuss Public Confusion, “Message Fatigue”
This article was originally published in The Pink Sheet Daily
FDA advisory committee will again consider whether consumers have an inaccurate understanding of drug risks or are so overwhelmed by messages about them that they discount the warnings.
You may also be interested in...
FDA's Risk Communications Advisory Committee is set to discuss how quantitative risk information can be presented in such a way as to inform rather than mislead consumers.
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.